CN115814020A - Traditional Chinese medicine composition for treating ventricular arrhythmia and application thereof - Google Patents
Traditional Chinese medicine composition for treating ventricular arrhythmia and application thereof Download PDFInfo
- Publication number
- CN115814020A CN115814020A CN202211332127.4A CN202211332127A CN115814020A CN 115814020 A CN115814020 A CN 115814020A CN 202211332127 A CN202211332127 A CN 202211332127A CN 115814020 A CN115814020 A CN 115814020A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- traditional chinese
- medicine composition
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for treating ventricular arrhythmia and application thereof. The traditional Chinese medicine composition comprises the following raw material medicines: astragalus membranaceus, rhizoma polygonati, mulberry, radix pseudostellariae, radix rehmanniae recen, rhizoma nardostachyos, coptis chinensis, cassia twig, spina date seed, platycladi seed, pseudo-ginseng and raw dragon bone. The invention also discloses a preparation method of the traditional Chinese medicine composition and application of the traditional Chinese medicine composition in preparing a medicine for treating ventricular arrhythmia. The traditional Chinese medicine composition disclosed by the invention can effectively reduce the ventricular premature beats and the premature beats times of a patient in percentage of heart beats, reduce the Myerburg grading score of the patient, improve the clinical symptoms of palpitation, chest distress, short breath, dysphoria, dizziness, hypodynamia, chest pain, tinnitus and the like of the patient, improve the life quality of the patient, and is safe and effective in clinical application.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicine. More particularly, relates to a traditional Chinese medicine composition for treating ventricular arrhythmia and application thereof.
Background
Ventricular arrhythmia (mainly including Premature Ventricular Contractions (PVCs)) is one of the most common clinical arrhythmias, the attack population is wide, the induction factors are more, the attack population is more and more younger in recent years, the prognosis can be greatly different according to different individual conditions of patients, and serious patients can have ventricular fibrillation to endanger life. It has been generally accepted that patients with functional ventricular arrhythmias that are asymptomatic should not be treated with drugs. However, with the continuing advancement of medical care, studies have shown that functional ventricular premature development, which is long-term asymptomatic, if left untreated, will also induce cardiac remodeling and cardiac insufficiency, rather than being completely benign. Therefore, the treatment of ventricular arrhythmias is receiving more and more attention.
At present, the western medicine treatment of ventricular arrhythmia is mainly divided into antiarrhythmic drug treatment, intervention and other surgical therapies. The antiarrhythmic drug mainly takes sodium channel blocker, beta receptor blocker, potassium channel blocker, slow calcium channel blocker and other drugs as main drugs, has certain curative effect, but is easy to generate drug resistance when being taken by patients, western medicines have adverse reactions such as arrhythmia, myocardial contraction inhibition and the like, and the difference of curative effect is large after being taken by the patients. With the development of mapping and ablation technology, radiofrequency ablation is increasingly one of the main methods for treating ventricular arrhythmia, patients with ventricular arrhythmia with obvious symptoms or left ventricular insufficiency are more likely to benefit from radiofrequency ablation treatment, but as an invasive treatment means, radiofrequency ablation has certain complications and is easy to relapse after operation, and the method is more beneficial to treatment of multi-source ventricular arrhythmia.
The traditional Chinese medicine has great advantages for treating ventricular arrhythmia, can greatly improve clinical symptoms for patients with various types of ventricular arrhythmia, can be taken for a long time, plays a role in synergism and attenuation, has a long-term curative effect superior to that of western medicines, gradually becomes a primary choice for clinically treating ventricular arrhythmia, and has a wide prospect. However, the traditional Chinese medicine specially aiming at improving objective evaluation indexes such as ventricular premature beat frequency, premature beat percentage, myerburg grading evaluation and the like is lacked in the traditional Chinese medicine reported at present. Therefore, the development of a more effective Chinese medicinal composition for treating ventricular arrhythmia is still a goal of the clinical workers of traditional Chinese medicine.
Disclosure of Invention
In view of the above technical problems, an object of the present invention is to provide a novel Chinese medicinal composition, which can effectively treat ventricular arrhythmia, and particularly, can effectively improve ventricular premature beat frequency, premature beat percentage, myerburg grading evaluation, and clinical symptoms and life quality of patients.
The invention also aims to provide application of the traditional Chinese medicine composition in preparing a medicine for treating ventricular arrhythmia.
In order to achieve the purpose, the invention adopts the following technical scheme:
in a first aspect, the invention provides a traditional Chinese medicine composition for treating ventricular arrhythmia, which mainly comprises the following raw material medicines: astragalus root, rhizoma polygonati, mulberry, radix pseudostellariae, radix rehmanniae recen, nardostachys chinensis, coptis chinensis, cassia twig, spina date seed, platycladi seed, pseudo-ginseng and raw keel.
Preferably, the traditional Chinese medicine composition comprises the following raw material medicines in parts by weight: 10-50 parts of astragalus membranaceus, 10-50 parts of rhizoma polygonati, 10-50 parts of mulberry, 10-50 parts of radix pseudostellariae, 10-50 parts of radix rehmanniae recen, 5-30 parts of rhizoma nardostachyos, 3-10 parts of cassia twig, 3-10 parts of coptis chinensis, 10-50 parts of spina date seed, 10-50 parts of platycladi seed, 2-10 parts of pseudo-ginseng and 10-50 parts of raw keel.
The selection of the medicinal materials is obtained by the inventor through groping and summarizing clinical experiences for many years according to the theory of traditional Chinese medicine, and the medicinal materials are analyzed, researched and verified. The Chinese medicinal composition has effects of replenishing kidney essence, nourishing heart, invigorating qi, promoting blood circulation, and tranquilizing mind. Mainly treats patients with heart-kidney disharmony type ventricular arrhythmia, with symptoms of palpitation, chest distress, hypodynamia, short breath, insomnia, easy fright and the like.
In the prescription of the invention, astragalus root, radix astragali is sweet and slightly warm, and enters spleen and lung meridians, so that the formula of the invention, named in Ben Cao Hui Yan, is used for tonifying lung and spleen, and Shi Wei Lianhan, and expelling wind and removing toxicity. Astragalus root is the essential drug for invigorating spleen-stomach and qi, and can tonify qi of spleen and lung, thus benefiting defensive qi, consolidating exterior, benefiting qi and nourishing blood. Rhizoma polygonati is sweet and neutral, enters lung, spleen and kidney channels, has the functions of strengthening spleen, moistening lung, tonifying kidney and tonifying three yin, and can tonify deficiency, stop cold and heat and fill essence and marrow … … in compendium of materia medica, in particular is good at tonifying kidney, moistening lung, tonifying qi and nourishing yin. The mulberry is sweet, sour and cold in nature, enters heart, liver and kidney channels, has the functions of nourishing yin and blood, promoting fluid production and moistening dryness, can tonify yin of liver and kidney, can tonify blood and nourish liver, and has the meaning of homology of liver and kidney and generation of essence and blood. Ben Cao Jing Shu (the book of materia Medica Prime and Dredging): mulberry, fructus Mori, being sweet in flavor and cold in property, can tonify blood and remove heat, is a blood-cooling, blood-enriching and yin-nourishing herb … …, which pertains to yin in five zang organs, so benefiting yin and benefiting five zang organs. Radix astragali is combined with rhizoma polygonati and mulberry to play the role of nourishing kidney, qi and yin together, and is used as a monarch drug. Moreover, the mulberry and the sealwort are also the medicinal and edible products, so the medicine properties are mild, and the long-term taking is facilitated.
Sheng Di Huang is sweet and cold in nature and can nourish yin, and bitter cold can discharge heat, entering heart, liver and kidney meridians, entering kidney meridian to nourish yin to reduce fire, and nourish yin to discharge fluid and discharge heat. It is good at nourishing yin, nourishing blood and cooling blood. In the section of Ben Cao Xin Hui, its action is specially for cooling blood and stopping bleeding, and it is good at treating jin Jiang, preventing abortion, dredging meridians, stopping metrorrhagia and metrostaxis. Radix pseudostellariae is sweet and slightly bitter in taste, has the effects of tonifying qi, strengthening spleen, promoting the production of body fluid and moistening lung, has the advantages of tonifying primordial qi and spleen and lung qi by using radix ginseng and radix codonopsitis, and belongs to a clearing and tonifying product in qi tonifying medicines. The radix rehmanniae is compatible with the radix pseudostellariae and is used as ministerial drugs, and the radix rehmanniae and the radix pseudostellariae are mutually used, so that the effects of tonifying qi and spleen, nourishing yin and blood are enhanced.
The spina date seed has the effects of nourishing heart yin, benefiting liver blood, soothing nerves and stabilizing palpitation; baizi ren is sweet in taste and moist in nature, mild in property, and mainly enters heart meridian, so it has actions of nourishing heart, tranquilizing mind, checking sweat and moistening intestines. The compendium of materia Medica calls it: the two medicines are used as ministerial medicines for nourishing heart, soothing nerves and calming palpitation.
Gan Song is pungent, sweet and warm, has the actions of activating spleen and relieving depression, moving qi and activating yang, pungent and dispersing without consuming body fluids and blood, and combined with each other for palpitation due to qi deficiency and blood stasis. Modern pharmacological research also shows that the valeric acid contained in the nardostachys chinensis bunge has the effect of resisting arrhythmia, the nardostachys chinensis bunge volatile oil which mainly comprises terpenoid has the effects of resisting tumor, inhibiting bacteria, resisting inflammation, resisting arrhythmia, protecting cardiac muscle cells and the like, and the arrhythmia resisting action target and the electrophysiological mechanism of the nardostachys chinensis bunge play a role by inhibiting injurious inward current.
Coptis root, rhizoma Coptidis, bitter in taste and cold in nature, enters heart, spleen, stomach, liver, gallbladder and large intestine meridians, excels in purging the fire of shaoyin heart meridian, and can clear heart fire and relieve restlessness, and prevent up-flaming of heart fire; gui Zhi is pungent and warm in property, enters heart, lung, kidney and bladder meridians, and can regulate Ying and Wei, warm middle energizer to dispel cold and descend adverse rise and fall. The two herbs are combined together, and the combination of cold and warm herbs can unblock heart and kidney, so it is indicated by Jietai Wan for water and fire.
Long Gu is sweet and neutral and enters heart and kidney meridians to relieve convulsion, induce tranquilization and astringe and subdue yang, so it is an adjuvant drug in Ben Cao gang mu for tonifying kidney, relieving convulsion, stopping yin malaria, removing dampness, rectocele, promoting tissue regeneration and healing wound, and combined with Gui Zhi to lower blood pressure and stop palpitation.
Finally, the pseudo-ginseng is used for promoting blood circulation to remove blood stasis, and the characteristics of stopping bleeding without retaining blood stasis and removing blood stasis without damaging vital qi are taken into consideration for the common basic pathogenesis of heart-vessel blockage of patients with cardiovascular diseases on the basis of regulating and treating heart and kidney.
The medicines are combined to regulate heart and kidney, so as to achieve the effects of nourishing kidney and heart, tonifying qi, activating blood and calming nerves.
Illustratively, the traditional Chinese medicine composition for treating ventricular arrhythmia comprises the following raw material medicines in parts by weight: 10-30 parts of astragalus membranaceus, 10-30 parts of rhizoma polygonati, 10-30 parts of mulberry, 10-30 parts of radix pseudostellariae, 10-30 parts of radix rehmanniae recen, 5-30 parts of rhizoma nardostachyos, 3-10 parts of coptis chinensis, 3-10 parts of cassia twig, 10-30 parts of spina date seed, 10-30 parts of platycladi seed, 2-10 parts of pseudo-ginseng and 10-30 parts of raw keel.
Illustratively, the traditional Chinese medicine composition for treating ventricular arrhythmia comprises the following raw material medicines in parts by weight: 20 parts of astragalus membranaceus, 15 parts of rhizoma polygonati, 15 parts of mulberry, 15 parts of radix pseudostellariae, 15 parts of radix rehmanniae recen, 12 parts of nardostachys chinensis, 9 parts of coptis chinensis, 6 parts of cassia twig, 15 parts of spina date seed, 15 parts of platycladi seed, 6 parts of pseudo-ginseng and 30 parts of raw keel.
Illustratively, the traditional Chinese medicine composition for treating ventricular arrhythmia comprises the following raw material medicines in parts by weight: 20 parts of astragalus membranaceus, 15 parts of rhizoma polygonati, 15 parts of mulberry, 20 parts of radix pseudostellariae, 15 parts of radix rehmanniae recen, 15 parts of nardostachys chinensis, 9 parts of coptis chinensis, 6 parts of cassia twig, 15 parts of spina date seed, 15 parts of platycladi seed, 6 parts of pseudo-ginseng and 30 parts of raw keel.
Illustratively, the traditional Chinese medicine composition for treating ventricular arrhythmia comprises the following raw material medicines in parts by weight: 20 parts of astragalus membranaceus, 15 parts of rhizoma polygonati, 15 parts of mulberry, 15 parts of radix pseudostellariae, 10 parts of radix rehmanniae recen, 15 parts of nardostachys chinensis, 6 parts of coptis chinensis, 6 parts of cassia twig, 15 parts of spina date seed, 15 parts of platycladi seed, 3 parts of pseudo-ginseng and 30 parts of raw keel.
The raw materials of the traditional Chinese medicine composition form a basic recipe, and in a specific implementation mode, the traditional Chinese medicine composition can be adjusted on the basis of clinical symptoms so as to achieve the purposes of treating ventricular arrhythmia and improving certain special clinical symptoms, further enhance the adaptability of the traditional Chinese medicine composition and improve the treatment effect. Such adjustments made based on the basic invention of the present invention are also within the scope of the present application.
For example, radix Sophorae Flavescentis and Concha Margaritifera can be added for patients with excessive heart fire and uneasiness; for dry mouth and tongue due to fire excess from yin deficiency, radix Ophiopogonis and fructus Schisandrae chinensis can be added to obtain powder for harmonizing pulse; bupleuri radix, radix Paeoniae alba, and rhizoma Cyperi can be added for patients with stagnation of qi due to stagnation of liver-qi and chest distress; for chronic diseases with obstruction of collaterals and blood stasis, radix Angelicae sinensis may be added.
In a second aspect, the invention provides a preparation method of the above traditional Chinese medicine composition for treating ventricular arrhythmia, which comprises the following steps: taking radix astragali, rhizoma Polygonati, mori fructus, radix Pseudostellariae, radix rehmanniae, rhizoma Nardostachyos, coptidis rhizoma, ramulus Cinnamomi, semen Ziziphi Spinosae, semen Platycladi, notoginseng radix and Os Draconis according to formula, decocting with water twice, filtering, and mixing filtrates.
Further, for convenience of storage, the above preparation method may further comprise concentrating the filtrate into fluid extract, spray drying, and sieving to obtain dry extract powder.
Further, in the preparation method, exemplarily, the water adding amount is 10-15 times of the total mass of the raw material medicines each time; the time for decoction is that micro-boiling is kept for 1-2 hours for the first time, and micro-boiling is kept for 0.5-1 hour for the second time; the fluid extract has a relative density of 1.30-1.35 measured at 60 deg.C. The technological parameters of spray drying are as follows: the air inlet temperature is 165-195 ℃, and the air outlet temperature is: 80-105 ℃.
In a third aspect, the invention provides a medicament for treating ventricular arrhythmia, which takes the traditional Chinese medicine composition as an active ingredient.
According to actual needs, the medicine can also comprise pharmaceutically acceptable auxiliary materials. Making into various preparations such as decoction, granule, pill, capsule, tablet, powder, oral liquid, etc. by conventional preparation process.
Illustratively, the dry extract powder (sieved by a 80-mesh sieve) is uniformly mixed and prepared into granules of 12-40 meshes by adopting dry granulation.
The invention also provides application of the traditional Chinese medicine composition in preparing a medicine for treating ventricular arrhythmia.
In addition, unless otherwise specified, all the raw material drugs of the traditional Chinese medicine composition can be commercially available, and the traditional Chinese medicine composition in any range including any value between the end values and any sub-range composed of any value between the end values or any value between the end values can achieve the purpose of treating ventricular arrhythmia.
The invention has the following beneficial effects:
the traditional Chinese medicine composition can effectively reduce the number of premature beats of a patient, reduce the Myerburg grading score of the patient, improve the clinical symptoms of palpitation, chest distress, hypodynamia, shortness of breath, spontaneous perspiration, night sweat and the like of the patient, improve the clinical life quality of the patient, is safe and effective in clinical application, and does not find adverse reactions at present.
Detailed Description
In order to more clearly illustrate the invention, the invention is further described below in connection with preferred embodiments. It is to be understood by persons skilled in the art that the following detailed description is illustrative and not restrictive, and is not to be taken as limiting the scope of the invention.
Example 1A Chinese medicinal composition for treating ventricular arrhythmia
The formula of the raw material medicine is as follows: 20g of astragalus membranaceus, 15g of rhizoma polygonati, 15g of mulberry, 15g of radix pseudostellariae, 15g of radix rehmanniae recen, 12g of rhizoma nardostachyos, 9g of coptis chinensis, 6g of cassia twig, 15g of spina date seed, 15g of platycladi seed, 6g of pseudo-ginseng and 30g of raw keel.
Decocting the above twelve raw materials in 10 times of water, heating to boil, maintaining slightly boiling for 1-2 hr, and vacuum filtering (200 mesh); decocting the two decoctions with 10 times of water, heating to boil, maintaining slightly boiling for 0.5-1 hr, filtering (200 mesh), and mixing filtrates.
Example 2A Chinese medicinal composition for the treatment of ventricular arrhythmia
The formula of the raw material medicine is as follows: 20g of astragalus membranaceus, 15g of rhizoma polygonati, 15g of mulberry, 20g of radix pseudostellariae, 15g of radix rehmanniae recen, 15g of rhizoma nardostachyos, 9g of coptis chinensis, 6g of cassia twig, 15g of spina date seed, 15g of platycladi seed, 6g of pseudo-ginseng and 30g of raw dragon bone.
Decocting the above twelve raw materials in 10 times of water, heating to boil, maintaining slightly boiling for 1-2 hr, and vacuum filtering (200 mesh); decocting the second decoction with 10 times of water, heating to boil, maintaining slightly boiling for 0.5-1 hr, filtering (200 mesh), mixing filtrates, concentrating the filtrate to appropriate amount (fluid extract with relative density of 1.30-1.35 (60 deg.C)), spray drying, pulverizing, and sieving to obtain dry extract powder.
EXAMPLE 3A drug (granule) for the treatment of ventricular arrhythmia
The formula of the raw material medicine is as follows: 20g of astragalus membranaceus, 15g of rhizoma polygonati, 15g of mulberry, 15g of radix pseudostellariae, 10g of radix rehmanniae recen, 15g of rhizoma nardostachyos, 6g of coptis chinensis, 6g of cassia twig, 15g of spina date seed, 15g of platycladi seed, 3g of pseudo-ginseng and 30g of raw keel.
Decocting the above twelve raw materials in 10 times of water, heating to boil, maintaining slightly boiling for 1-2 hr, and vacuum filtering (200 mesh); decocting the two decoctions with 10 times of water, heating to boil, maintaining slightly boiling for 0.5-1 hr, vacuum filtering (200 mesh), mixing filtrates, concentrating the filtrate to appropriate amount (relative density of 1.30-1.35 (60 deg.C) of fluid extract), spray drying (air inlet temperature 165-195 deg.C, air outlet temperature 80-105 deg.C), sieving with 80 mesh sieve to obtain dry extract powder, adding appropriate amount of dextrin, mixing, and dry granulating.
Example 4 efficacy test and safety of the Chinese medicinal composition for treating heart-kidney imbalance type ventricular arrhythmia
In order to further improve the clinical curative effect, the prescription of the invention is continuously optimized and improved, samples are expanded on the basis of the previous clinical research for further research, and the results of partial completion are as follows:
the source of the cases is: the medical inpatients and outpatients of Guangan Hospital of Chinese academy of science of traditional Chinese medicine in 2019-2021.
The research method comprises the following steps: 48 patients with ventricular arrhythmias meeting the exclusion criteria were randomly grouped in a ratio of 1:1, 24 in the experimental group and 24 in the control group. The test group patients take the traditional Chinese medicine composition, and the control group patients take the metoprolol tartrate tablets orally. The treatment course is 4 weeks. Recording the 24-hour dynamic electrocardiogram results of two groups of patients before and after treatment, the Chinese medicine clinical symptom integral and safety index.
Study medication:
treatment groups: decoction (prepared according to the preparation method of example 1), one dose of the prescription: 20g of astragalus membranaceus, 15g of rhizoma polygonati, 15g of mulberry, 15g of radix pseudostellariae, 15g of radix rehmanniae recen, 12g of rhizoma nardostachyos, 9g of coptis chinensis, 6g of cassia twig, 15g of spina date seed, 15g of platycladi seed, 6g of pseudo-ginseng and 30g of raw keel; one dose is taken every day, and the medicine is taken in the morning and at night.
Control group: metoprolol tartrate tablets (Aslicon pharmaceutical Co., ltd., national Standard H32025391) at 12.5 mg/dose, 2 times daily.
The patients have coronary heart disease, hypertension, diabetes, hyperlipidemia and other basic diseases, corresponding drug therapy is continuously given during the treatment period, and other antiarrhythmic western medicines and other traditional Chinese medicine preparations are stopped taking during the treatment period.
The research results are as follows: the total number of ventricular arrhythmia patients with complete data collected is 48, wherein 20 out-patients and 28 in-patients are in hospital, all the cases meet the inclusion standard and are randomly divided into two groups, wherein 24 cases in a treatment group and 24 cases in a control group; 18 men and 30 women, the age is 45-80 years; the longest course of disease is 40 years, and the shortest course of disease is 1 month; 12 patients with hypertension, 25 patients with hyperlipidemia, 19 patients with diabetes, 7 patients with other diseases, and 3 patients without diseases. The compliance of the treatment group in the test process is good, and 2 cases of the control group are dropped off, and the test subjects quit automatically.
(1) Effects on ventricular premature beat count, percent premature beat to beat, and average heart rate
1.1 comparison of ventricular premature beats before and after two groups of treatments
The ventricular premature beat frequency and the premature beat percentage of the two groups of patients are compared before and after treatment, the improvement is different, and the statistical analysis shows that the ventricular premature beat frequency and the premature beat percentage have significant difference (P < 0.05). The treated group and the control group are compared between the group by the number of premature beats and the percentage of premature beats to the heart beat, the number of premature beats and the percentage of premature beats to the heart beat of the treated group are both smaller than those of the control group, but the difference is not statistically significant (P is more than 0.05), and the two groups can effectively reduce the number of premature beats and the percentage of premature beats to the heart beat.
The average heart rates of two groups of patients are compared before and after treatment, no obvious change exists before and after treatment, and the difference has no statistical significance (P > 0.05); the mean heart rate of the control group is obviously reduced after treatment compared with that before treatment, has statistical significance (P < 0.05), and proves that the mean heart rate of the patient can be reduced when the control group is used for treating ventricular premature beat. See tables 1-3 for details.
TABLE 1 comparison of ventricular premature beat frequency before and after two groups of treatment
| Group of | Number of instances n | Before treatment | After treatment | P value |
| Treatment group | 24 | 12956.01±10734.21 | 4121.52±5378.60 | 0.00 |
| Control group | 22 | 12076.58±10619.78 | 6798.31±7993.29 | 0.00 |
| P | 0.78 | 0.27 |
TABLE 2 comparison of ventricular premature beat ratios before and after two treatments
| Group of | Number of instances n | Before treatment | After treatment | P value |
| Treatment group | 24 | 12.72±12.78 | 3.97±6.20 | 0.00 |
| Control group | 22 | 12.07±9.89 | 6.58±6.91 | 0.00 |
| P | 0.94 | 0.09 |
TABLE 3 comparison of mean Heart Rate before and after two groups of treatments
| Group of | Number of instances n | Before treatment | After treatment | P value |
| Treatment group | 24 | 69.38±7.31 | 68.35±9.83 | 0.57 |
| Control group | 22 | 68.87±6.35 | 64.01±5.31 | 0.02 |
| P | 0.92 | 0.03 |
1.2 evaluation of curative effects of two groups of ventricular premature beats before and after treatment
The ventricular premature beats of the two groups of patients are improved in different degrees, wherein the total effective rate of improving the ventricular premature beats of the treatment group is 79.2 percent, the total effective rate of improving the ventricular premature beats of the control group is 50.0 percent, the effective rates of the ventricular premature beats of the two groups of patients are statistically analyzed, and have significant difference (P < 0.05), and the curative effect of the treatment group is better than that of the control group, which is shown in table 4.
TABLE 4 evaluation and comparison of curative effect of ventricular premature beat before and after two groups of treatment
| Group of | Number of instances n | Recovery (%) | Significant effect (%) | Effective (%) | Null (%) |
| Treatment group | 24 | 7(29.2％) | 5(20.8％) | 7(29.2％) | 5(20.8％) |
| Control group | 22 | 4(18.2％) | 2(9.1％) | 5(22.7％) | 11(50.0％) |
| Total up to | 46 | 11(23.9％) | 7(15.2％) | 12(26.1％) | 16(34.8％) |
Z＝-4.45，P＝0.03
1.3 assessment of Myerburg grade efficacy before and after two groups of treatments
The Myerburg score of the two groups after treatment is compared before and after treatment, the two groups are reduced, wherein the P of the treatment group is less than 0.05, and the statistical significance is achieved. After treatment, the two groups are compared between groups, the Myerburg average score of the treatment group is lower than that of the control group, the P is more than 0.05 through the wilcoxon test, and the difference of the two groups has no statistical significance, which is shown in a table 5.
Compared with the Myerburg graded curative effect evaluation of a treatment group and a control group after treatment, 24 patients in the treatment group have 9 significant effects and 5 effective patients, and the effective rate is 58.3 percent. The control group has 22 patients, 6 patients with obvious effect and 4 patients with effect, and the effective rate is 45.5%. The treatment group and the control group can effectively improve the Myerburg grading score when treating ventricular premature beat, and the clinical effective rate of the treatment group is higher than that of the control group. The effective rates of the two groups are compared, the P is more than 0.05 by chi-square test, and the two groups have no obvious statistical difference on improving the Myerburg grading score, which is shown in Table 6.
TABLE 5 comparison of Myerburg scores before and after treatment in two groups
| Group of | Number of instances n | Before treatment | After treatment | P value |
| Treatment group | 24 | 7.67±1.27 | 3.23±1.83 | 0.04 |
| Control group | 22 | 7.28±1.36 | 5.04±1.91 | 0.29 |
| P | 0.92 | 0.09 |
TABLE 6 comparison of the Myerburg graded efficacy before and after treatment in two groups
| Group of | Number of instances n | Show effect (%) | Effective (%) | Null (%) | P |
| Treatment group | 24 | 9(37.5％) | 5(20.8％) | 10(41.7％) | 0.18 |
| Control group | 22 | 6(27.3％) | 4(18.2％) | 12(54.5％) | |
| Total up to | 46 | 15(32.6％) | 9(20.0％) | 22(48.7％) |
(2) Influence on the syndrome of traditional Chinese medicine
2.1 Total integral comparison of Chinese medicine syndrome before and after two groups of treatments
The total integral of the traditional Chinese medicine syndromes after treatment of the treatment group and the control group is reduced compared with that before treatment, and the statistical difference (P < 0.01) is provided, which indicates that the total integral of the traditional Chinese medicine syndromes after treatment is improved.
After treatment, the total integral groups of the traditional Chinese medicine syndromes are compared, the treatment group is lower than the control group, and has statistical difference (P is less than 0.01), so that the treatment group is better than the control group in the aspect of improving the traditional Chinese medicine syndromes, and the specific table is shown in table 7.
TABLE 7 Total integral comparison of Chinese medicine syndrome before and after two groups of treatment
2.2 score comparison of Individual symptoms before and after treatment
After treatment, the single symptoms of the traditional Chinese medicine such as palpitation, chest distress, short breath, dysphoria, dizziness, hypodynamia, chest pain, tinnitus, soreness and weakness of waist and knees and the like of a patient in a treatment group are improved (P is less than 0.01); the patients in the control group have improved symptoms such as palpitation, chest distress, short breath, dysphoria, dizziness, hypodynamia, chest pain, tinnitus and the like (P is less than 0.05), but have no obvious improvement on the symptoms of soreness and weakness of waist and knees (P is more than 0.05), and the comparison of the two groups of curative effects has statistical significance (P is less than 0.05). Compared with the treatment groups of two groups of patients, the treatment group is obviously superior to the control group in the aspects of improving symptoms such as palpitation, chest distress, short breath, dysphoria, dizziness, hypodynamia, chest pain, tinnitus, soreness and weakness of waist and knees and the like (P is less than 0.05). See tables 8-16 for details.
TABLE 8 comparison of palpitations before and after treatment in two groups
| Group of | Number of instances n | Before treatment | After treatment | P value |
| Treatment group | 24 | 3.67±1.18 | 1.67±0.92 | 0.00 |
| Control group | 22 | 3.86±1.33 | 3.00±1.28 | 0.03 |
| P | 0.57 | 0.00 |
TABLE 9 comparison of chest distress symptoms before and after two groups of treatments
| Group of | Number of instances n | Before treatment | After treatment | P value |
| Treatment group | 24 | 3.40±1.30 | 1.07±1.14 | 0.00 |
| Control group | 22 | 3.07±1.15 | 2.64±1.10 | 0.08 |
| P | 0.31 | 0.00 |
TABLE 10 comparison of symptoms of shortness of breath before and after two groups of treatment
| Group of | Number of instances n | Before treatment | After treatment | P value |
| Treatment group | 24 | 3.60±1.33 | 1.43±1.17 | 0.00 |
| Control group | 22 | 3.71±1.18 | 2.64±1.34 | 0.00 |
| P | 0.73 | 0.00 |
TABLE 11 comparison of dysphoria before and after two groups of treatments
| Group of | Number of instances n | Before treatment | After treatment | P value |
| Treatment group | 24 | 3.53±1.63 | 1.40±1.19 | 0.00 |
| Control group | 22 | 3.29±1.24 | 3.21±0.99 | 0.77 |
| P | 0.52 | 0.00 |
TABLE 12 comparison of dizziness symptoms before and after treatment of the two groups
| Group of | Number of instances n | Before treatment | After treatment | P value |
| Treatment group | 24 | 2.12±0.75 | 1.17±0.63 | 0.03 |
| Control group | 22 | 2.23±0.86 | 1.56±0.64 | 0.04 |
| P | 0.23 | 0.04 |
TABLE 13 comparison of the symptoms of asthenia before and after two groups of treatment
| Group of | Number of instances n | Before treatment | After treatment | P value |
| Treatment group | 24 | 2.00±0.95 | 0.47±0.63 | 0.00 |
| Control group | 22 | 2.29±0.85 | 1.46±0.64 | 0.00 |
| P | 0.23 | 0.00 |
TABLE 14 comparison of chest pain symptoms before and after treatment in two groups
| Group of | Number of instances n | Before treatment | After treatment | P value |
| Treatment group | 30 | 2.53±0.68 | 0.40±0.56 | 0.00 |
| Control group | 28 | 2.29±0.66 | 1.29±0.60 | 0.00 |
| P | 0.17 | 0.00 |
TABLE 15 comparison of tinnitus symptoms before and after treatment in two groups
| Group of | Number of instances n | Before treatment | After treatment | P value |
| Treatment group | 24 | 2.33±0.88 | 0.40±0.50 | 0.00 |
| Control group | 22 | 2.32±0.72 | 1.11±0.57 | 0.00 |
| P | 0.96 | 0.00 |
TABLE 16 comparison of the soreness and weakness of the waist and knees before and after treatment of the two groups
| Group of | Number of instances n | Before treatment | After treatment | P value |
| Treatment group | 24 | 1.17±0.70 | 0.51±0.50 | 0.00 |
| Control group | 22 | 1.14±0.65 | 1.11±0.57 | 0.76 |
| P | 0.89 | 0.00 |
2.3 comparison of the total curative effects of the two groups of syndromes before and after treatment
The total effective rate of the traditional Chinese medicine syndrome curative effect after treatment of the treatment groups is 87.5 percent; the total effective rate of the traditional Chinese medicine syndrome curative effect after treatment of the control group is 54.5%, and the statistical difference (P < 0.05) is obtained by comparing the two groups of patients, which shows that the total traditional Chinese medicine syndrome curative effect of the treatment group is better than that of the control group after treatment, and is shown in table 17.
TABLE 17 comparison of the total therapeutic effects of the two groups of syndromes before and after treatment
| Group of | Number of instances n | Recovery (%) | Significant effect (%) | Effective (%) | Null (%) |
| Treatment group | 24 | 1(4.2％) | 12(50.0％) | 8(33.3％) | 3(12.5％) |
| Control group | 22 | 0(0.0％) | 4(18.2％) | 8(36.4％) | 10(45.4％) |
| Total up to | 46 | 0(0.0％) | 15(32.6％) | 16(34.8％) | 15(32.6％) |
Z＝-2.12，P＝0.03
(3) Quality of life Scale (SF-36) score comparison
The baseline levels of the Physiological Function (PF) scale were consistent for both SF-36 quality of life scales. The change of Physiological Function (PF) after treatment compared with baseline is increased by 8.6 points on average, the difference has statistical significance (P is less than 0.01) compared before and after treatment in the group, the difference is increased by 2.3 points on average compared before and after treatment in the group, and the difference has no statistical significance (P is more than 0.05) compared before and after treatment in the group. Compared with the treatment group, the treatment group has statistical significance (P is less than 0.05), which indicates that the treatment group is superior to the control group on the scale of improving the quality of life of patients. See table 18 for details.
TABLE 18 comparison of Physiological Function (PF) Scale for two pre-and post-treatment SF-36 quality of Life scales
| Group of | Number of instances n | Before treatment | After treatment | P value |
| Treatment group | 24 | 80.09±13.78 | 88.71±10.89 | 0.00 |
| Control group | 22 | 78.04±15.28 | 80.31±16.96 | 0.06 |
| P | 0.35 | 0.00 |
(4) Changes in blood pressure
The blood pressure (including systolic pressure and diastolic pressure) of the two groups of patients has no obvious change before and after treatment, and has no statistical significance (P is more than 0.05), and the details are shown in a table 19.
TABLE 19 comparison of blood pressure before and after treatment of two groups
(5) Adverse reactions and safety check
Blood routine and liver and kidney functions (BUN, cr, ALT and AST) tests were performed on 46 patients before and after treatment, and no significant change was observed in the indices before and after treatment (P > 0.05). No adverse reaction is found in the control group and the treatment group in the treatment process. The details are shown in tables 20-21.
TABLE 20 comparison of blood routine results before and after treatment in two groups
TABLE 21 comparison of hepatic and renal function results before and after treatment in two groups
The research result shows that the traditional Chinese medicine composition for treating the ventricular arrhythmia patients with the heart-kidney imbalance can remarkably improve the clinical symptoms of the patients, reduce the ventricular arrhythmia of the patients and achieve satisfactory clinical curative effect. Meanwhile, the medicine has no adverse effect on the blood pressure level, the liver and kidney functions and the like of a patient, and has good safety. Researches show that the traditional Chinese medicine composition is safe and effective in treating ventricular arrhythmia.
EXAMPLE 5 typical cases
(1) The patient has a certain stone, a woman, a 37 year old, and an employee. Initial diagnosis at 26 month 01 in 2021.
The main complaints are: paroxysmal palpitation of half a year
The medical history: paroxysmal palpitation begins to appear half a year ago, each palpitation attack is related to work tension and fatigue, medicines such as betaleplate, mexiletine and the like are orally taken once, the effect is poor, the work and the life are obviously influenced, and a dynamic electrocardiogram is displayed in 12-month and 27-month 2020 of patients: sinus rhythm, mean heart rate 70bpm, frequent ventricular premature beats, partially bigeminal, partially trigeminal, and partially paired. The total number of the chamber early is 14531 times/24 h, the average time is 606 times per hour, and the chamber early proportion is 15.31%. Paired chamber early 3 pairs, bigeminal 163 matrix, and triple 4 matrix. Therefore, the clinic seeks further traditional Chinese medicine treatment. The symptoms at the time of arrival diagnosis are: palpitation, fatigue, aggravation after stress, restlessness, fatigue, lassitude, poor sleep. The tongue is red, dark, wiry and thready, sometimes with intermittent pulses.
Traditional Chinese medicine diagnosis: palpitations; and (3) Western diagnosis: arrhythmias are frequently preceded by premature ventricular contractions.
Syndrome differentiation: disharmony between the heart and kidney.
Therapeutic method: nourish kidney and heart, tonify qi, activate blood and induce tranquilization.
Prescription: 20g of raw astragalus membranaceus, 15g of rhizoma polygonati, 15g of mulberry, 20g of radix pseudostellariae, 15g of radix rehmanniae recen, 15g of rhizoma nardostachyos, 9g of coptis chinensis, 6g of cassia twig, 15g of spina date seed, 15g of platycladi seed, 6g of pseudo-ginseng and 30g of raw dragon bone. 14 doses of water are decocted for oral dose, one dose is taken in a day.
And (3) return visit 1: in 2021, 27 days 02 and 27 months, the medical history is the same as that of the previous day, the patients take the medicine for about 1 month, the palpitation is obviously relieved, the spirit is obviously improved, and the sleep is also improved. And (3) rechecking the dynamic electrocardiogram: sinus rhythm, mean heart rate 72bpm, frequent ventricular premature beats, partially bigeminal, partially trigeminal, and elevated for a portion of the time period ST-T. The total number of the chamber-premature is 5196 times, the average time per hour is 219.627 times, and the chamber-premature ratio is 5.43 percent. Paired chambers early 0 pairs, bigeminal 405, and triple regular 174. The first 14 doses were taken sequentially.
And (3) return visit 2: 18 months 01 and 18 days 2022 with the same medical history, patients take the medicine intermittently for nearly 1 year in other places due to epidemic situations, so that the patients are in a mental state, have no worry, no fear and discomfort and have sleep. Examination of the dynamic electrocardiogram on 2022, 01, 16 months: sinus rhythm, average heart rate 59bpm. Occasional atrial premature beats and ventricular premature beats (multiple sources) are partially in a bigeminal rule and partially in a trigeminal rule. The total number of chamber-premature is 150 times, the average is 6 times per hour, and the chamber-premature ratio is 0.18%. Paired chamber early 0 pairs, bigeminy 1 matrix, and trigeminy 1 matrix. Supraventricular premature beats 12 times.
According to the language: the literature of Su Wen and Ping ren meteorology is characterized by: "it should take action under the breast, and pectoral cavity is also relieved. "this is the earliest description of the existing" deficiency-related palpitations ". Palpitation is located in the heart and related to five zang organs, manifesting as palpitation, intermittent pulse, accompanied by dizziness, chest distress and short breath. The patient in this example is a middle-aged female, and symptoms of palpitation and hypodynamia appear due to long-term work stress and fatigue. The oral administration of the western medicines betalake and mexiletine has poor effect. The inventor thinks that the patient has palpitation due to heart-qi deficiency, kidney-yin deficiency and blood stasis; the disease is marked by deficiency of origin and excess of origin, with deficiency of origin being the most critical. The heart is the root of deficiency of kidney yin and pectoral qi, and the symptoms of blood stasis and phlegm-heat are marked by blood stasis. The treatment is carried out by taking the methods of nourishing kidney and heart, tonifying qi, activating blood circulation and calming the nerves and by using the formula of nourishing kidney and heart and restoring pulse, the symptoms of palpitation and hypodynamia basically disappear after the intermittent administration for about 1 year, and the dynamic electrocardiogram examination indicates that the ventricular premature beat is obviously reduced. The prescription always treats the above medicines, has the same coordination of heart and kidney, nourishes kidney and nourishes heart, benefits qi and activates blood to calm the nerves, and has satisfactory curative effect.
It should be understood that the above-mentioned embodiments of the present invention are only examples for clearly illustrating the present invention, and are not intended to limit the embodiments of the present invention, and it will be obvious to those skilled in the art that other variations or modifications may be made on the basis of the above description, and all embodiments may not be exhaustive, and all obvious variations or modifications may be included within the scope of the present invention.
Claims (10)
1. A traditional Chinese medicine composition for treating ventricular arrhythmia is characterized by comprising the following raw material medicines: astragalus root, rhizoma polygonati, mulberry, radix pseudostellariae, radix rehmanniae recen, nardostachys chinensis, coptis chinensis, cassia twig, spina date seed, platycladi seed, pseudo-ginseng and raw keel.
2. The traditional Chinese medicine composition according to claim 1, which is characterized by comprising the following raw materials in parts by weight: 10-50 parts of astragalus membranaceus, 10-50 parts of rhizoma polygonati, 10-50 parts of mulberry, 10-50 parts of radix pseudostellariae, 10-50 parts of radix rehmanniae recen, 5-30 parts of rhizoma nardostachyos, 3-10 parts of coptis chinensis, 3-10 parts of cassia twig, 10-50 parts of spina date seeds, 10-50 parts of platycladi seeds, 2-10 parts of pseudo-ginseng and 10-50 parts of raw dragon bones.
3. The traditional Chinese medicine composition according to claim 1, which is characterized by comprising the following raw material medicines in parts by weight: 10-30 parts of astragalus membranaceus, 10-30 parts of rhizoma polygonati, 10-30 parts of mulberry, 10-30 parts of radix pseudostellariae, 10-30 parts of radix rehmanniae recen, 5-30 parts of rhizoma nardostachyos, 3-10 parts of coptis chinensis, 3-10 parts of cassia twig, 10-30 parts of spina date seeds, 10-30 parts of platycladi seeds, 2-10 parts of pseudo-ginseng and 10-30 parts of raw dragon bones.
4. The traditional Chinese medicine composition according to claim 1, which is characterized by comprising the following raw material medicines in parts by weight: 20 parts of astragalus membranaceus, 15 parts of rhizoma polygonati, 15 parts of mulberry, 15 parts of radix pseudostellariae, 15 parts of radix rehmanniae recen, 12 parts of nardostachys chinensis, 9 parts of coptis chinensis, 6 parts of cassia twig, 15 parts of spina date seed, 15 parts of platycladi seed, 6 parts of pseudo-ginseng and 30 parts of raw keel.
5. The traditional Chinese medicine composition according to claim 1, which is characterized by comprising the following raw material medicines in parts by weight: 20 parts of astragalus membranaceus, 15 parts of rhizoma polygonati, 15 parts of mulberry, 20 parts of radix pseudostellariae, 15 parts of radix rehmanniae recen, 15 parts of nardostachys chinensis, 9 parts of coptis chinensis, 6 parts of cassia twig, 15 parts of spina date seed, 15 parts of platycladi seed, 6 parts of pseudo-ginseng and 30 parts of raw keel.
6. The traditional Chinese medicine composition according to claim 1, which is characterized by comprising the following raw materials in parts by weight: 20 parts of astragalus membranaceus, 15 parts of rhizoma polygonati, 15 parts of mulberry, 15 parts of radix pseudostellariae, 10 parts of radix rehmanniae recen, 15 parts of rhizoma nardostachyos, 6 parts of coptis chinensis, 6 parts of cassia twig, 15 parts of spina date seed, 15 parts of platycladi seed, 3 parts of pseudo-ginseng and 30 parts of raw keel.
7. The method for preparing a Chinese medicinal composition for treating ventricular arrhythmia according to any one of claims 1 to 6, wherein the preparation method comprises the following steps: weighing radix astragali, rhizoma Polygonati, mori fructus, radix Pseudostellariae, radix rehmanniae, rhizoma Nardostachyos, coptidis rhizoma, ramulus Cinnamomi, semen Ziziphi Spinosae, semen Platycladi, notoginseng radix and Os Draconis according to formula, decocting with water twice, filtering, and mixing filtrates;
preferably, the preparation method further comprises the steps of concentrating the filtrate into clear paste, then spray drying and sieving.
8. A medicament for treating ventricular arrhythmia, which is characterized in that the medicament takes the traditional Chinese medicine composition as claimed in any one of claims 1 to 6 as an active ingredient;
preferably, the medicament further comprises pharmaceutically acceptable auxiliary materials.
9. The medicament of claim 8, wherein the medicament is in the form of decoction, granules, pills, capsules, tablets, powder or oral liquid.
10. Use of the Chinese medicinal composition of any one of claims 1-6 in the preparation of a medicament for treating ventricular arrhythmia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211332127.4A CN115814020B (en) | 2022-10-28 | 2022-10-28 | Traditional Chinese medicine composition for treating ventricular arrhythmia and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211332127.4A CN115814020B (en) | 2022-10-28 | 2022-10-28 | Traditional Chinese medicine composition for treating ventricular arrhythmia and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115814020A true CN115814020A (en) | 2023-03-21 |
| CN115814020B CN115814020B (en) | 2023-09-15 |
Family
ID=85525697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211332127.4A Active CN115814020B (en) | 2022-10-28 | 2022-10-28 | Traditional Chinese medicine composition for treating ventricular arrhythmia and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115814020B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106266014A (en) * | 2016-09-23 | 2017-01-04 | 四川金堂海纳生物医药技术研究所 | One is used for treating tachycardic Chinese medicine composition and preparation method thereof |
| CN111298019A (en) * | 2020-03-11 | 2020-06-19 | 河北省中医药科学院 | Traditional Chinese medicine for treating tachyarrhythmia |
-
2022
- 2022-10-28 CN CN202211332127.4A patent/CN115814020B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106266014A (en) * | 2016-09-23 | 2017-01-04 | 四川金堂海纳生物医药技术研究所 | One is used for treating tachycardic Chinese medicine composition and preparation method thereof |
| CN111298019A (en) * | 2020-03-11 | 2020-06-19 | 河北省中医药科学院 | Traditional Chinese medicine for treating tachyarrhythmia |
Non-Patent Citations (3)
| Title |
|---|
| 刘如秀等: "滋肾养心方治疗室性期前收缩心肾不交证的 临床疗效", 中西医结合心脑血管病杂志, vol. 17, no. 16, pages 2401 - 2404 * |
| 孟晓红等: "中药降律灵治疗心动过速76例临床观察", 中国中医药科技, vol. 13, no. 04, pages 239 * |
| 郭艳琼等: "刘如秀教授从肾论治心律失常验案举隅", 中西医结合心脑血管病杂志, vol. 19, no. 5, pages 859 - 861 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115814020B (en) | 2023-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101011522B (en) | Chinese traditional medicine for treating cardiopathy | |
| CN105920514A (en) | Traditional Chinese medicinal composition for treating metabolic syndrome | |
| CN104873705A (en) | Medicinal composition for treating angina pectoris of coronary heart disease and application thereof | |
| CN103893670B (en) | Traditional Chinese medicine pill used for treating cardia-cerebrovascular diseases | |
| CN102579610B (en) | Chinese medicinal composition for treating cerebral hemorrhage and preparation method thereof | |
| CN111298019A (en) | Traditional Chinese medicine for treating tachyarrhythmia | |
| CN105311492A (en) | Medicine for treating coronary atherosclerotic heart disease | |
| CN105056192A (en) | Traditional Chinese medicine composition for treating myocardial infarction and application thereof | |
| CN112316051B (en) | Traditional Chinese medicine composition for nourishing blood and reducing phlegm as well as traditional Chinese medicine preparation, preparation method and application thereof | |
| CN1970050B (en) | Pharmaceutical composition for treating arrhythmia and preparation process thereof | |
| CN102988938A (en) | Traditional Chinese medicine composition for treating arrhythmia or atrial fibrillation and preparation method thereof | |
| CN115814020B (en) | Traditional Chinese medicine composition for treating ventricular arrhythmia and application thereof | |
| CN105343761A (en) | Traditional Chinese medicine composition for treating myocardial infarction and preparation method thereof | |
| CN102861169B (en) | Traditional Chinese medicine compound for treating paroxysmal supraventricular tachycardia | |
| CN110882347A (en) | A Chinese medicinal composition for treating cardiovascular diseases | |
| CN104491318A (en) | Traditional Chinese preparation used for treating asthma and preparation method of traditional Chinese preparation | |
| CN103638428A (en) | Traditional Chinese medicinal composition for treating coronary heart disease | |
| CN112294901B (en) | Traditional Chinese medicine composition for treating supraventricular arrhythmia and preparation method and application thereof | |
| CN101152247A (en) | Pharmaceutical composition for cardiovascular and cerebrovascular diseases and method for preparing the same | |
| CN105311425A (en) | Application of pharmaceutical composition containing folium artemisiae argyi in preparing medicine for treating myocardial infarction | |
| CN111298067A (en) | Traditional Chinese medicine for treating myocarditis sequelae | |
| CN111773310A (en) | Traditional Chinese medicine composition for tonifying qi, nourishing yin and activating blood and preparation method thereof | |
| CN104706942A (en) | Medicine composition for treating cerebrocardiac syndrome and preparation method of medicine composition | |
| CN103463575B (en) | Traditional Chinese medicine for treating heart-spleen-deficiency type arrhythmia and preparation method thereof | |
| CN103656199A (en) | Traditional Chinese medicine for treating cough caused by kidney Yin deficiency |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |